Skip to main
VIGL
VIGL logo

Vigil Neuroscience (VIGL) Stock Forecast & Price Target

Vigil Neuroscience (VIGL) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 13%
Hold 38%
Sell 13%
Strong Sell 0%

Bulls say

Vigil Neuroscience Inc is positioned favorably due to its innovative approach in developing therapeutics targeting neurodegenerative diseases, particularly highlighted by promising data from the VG-3927 program, which showed a notable dose-dependent reduction in sTREM2 levels. The company has an exclusive collaboration with Sanofi, which emphasizes confidence in Vigil's technology and potential, alongside its robust Phase I clinical data that may attract further partnerships for commercialization. Additionally, Vigil is trading at a negative $25 million enterprise value, indicating significant upside potential as positive clinical outcomes could bolster stock performance and investor interest.

Bears say

Vigil Neuroscience Inc has experienced significant stock pressure, with shares declining by 26% following the ALEC TREM2 data readout, reflecting concerns over the company's performance and future prospects. The company reported a substantial net loss of $23.8 million for 4Q24, resulting in a GAAP EPS of $(0.57), which fell short of consensus expectations. Additionally, an increased valuation discount rate of 35% has led to a downward adjustment in the company's valuation target, raising concerns about its ability to meet commercial execution and market expectations.

Vigil Neuroscience (VIGL) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 13% recommend Buy, 38% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vigil Neuroscience and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vigil Neuroscience (VIGL) Forecast

Analysts have given Vigil Neuroscience (VIGL) a Buy based on their latest research and market trends.

According to 8 analysts, Vigil Neuroscience (VIGL) has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vigil Neuroscience (VIGL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.